AQUAVAN® (fospropofol disodium) Injection
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Procedural Sedation
Conditions
Procedural Sedation
Trial Timeline
May 1, 2006 → Dec 1, 2007
NCT ID
NCT00327392About AQUAVAN® (fospropofol disodium) Injection
AQUAVAN® (fospropofol disodium) Injection is a phase 2/3 stage product being developed by Eisai for Procedural Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT00327392. Target conditions include Procedural Sedation.
What happened to similar drugs?
1 of 1 similar drugs in Procedural Sedation were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00327392 | Phase 2/3 | Completed |
| NCT00306722 | Phase 3 | Completed |
Competing Products
2 competing products in Procedural Sedation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + Fentanyl | Eisai | Approved | 35 |
| Dexmedetomidine + Chloral hydrate | Pfizer | Phase 2 | 27 |